Skip to Content

Triple Inhaled Therapy Aids in Moderate-to-Very Severe COPD

THURSDAY, June 25, 2020 -- Triple therapy, including glucocorticoid at either of two dose levels, is beneficial for moderate-to-very severe chronic obstructive pulmonary disease (COPD), according to a study published online June 24 in the New England Journal of Medicine.

Klaus F. Rabe, M.D., Ph.D., from the German Center for Lung Research in Grosshansdorf, and colleagues conducted a 52-week, phase 3 trial to assess the efficacy and safety of triple therapy at two dose levels of inhaled glucocorticoid in patients with moderate-to-very severe COPD and at least one exacerbation in the previous year. A total of 8,509 patients were randomly assigned to receive either twice-daily inhaled doses of triple therapy (inhaled glucocorticoid [320 or 160 µg], a long-acting muscarinic antagonist [LAMA; glycopyrrolate], and a long-acting β2-agonist [LABA; formoterol]) or one of two dual therapies (glycopyrrolate plus formoterol or budesonide plus formoterol) in a 1:1:1:1 ratio.

The researchers found that the annual rates of moderate or severe exacerbations were 1.08 and 1.07 in the 320- and 160-µg budesonide triple therapy groups, respectively; 1.42 in the glycopyrrolate-formoterol group; and 1.24 in the budesonide-formoterol group. Compared with glycopyrrolate-formoterol or budesonide-formoterol, the rate was significantly lower with 320-µg glucocorticoid triple therapy (rate ratios, 0.76 and 0.87, respectively). Similarly lower rates were seen with 160-µg glucocorticoid triple therapy (rate ratios, 0.75 and 0.86, respectively).

"Our findings show the benefits of triple therapy with a budesonide-glycopyrrolate-formoterol combination over dual therapy with a LAMA-LABA or an inhaled glucocorticoid-LABA combination," the authors write.

The study was funded by AstraZeneca.

Abstract/Full Text (subscription or payment may be required)

© 2021 HealthDay. All rights reserved.

Read this next

Access to Pulmonary Rehab Limited for Many COPD Patients

MONDAY, May 24, 2021 -- About 60 percent of individuals with chronic obstructive pulmonary disorder (COPD) have a pulmonary rehabilitation (PR) center within a 10-mile radius...

Exposure to Ambient Air Pollutants May Up BP in Children, Teens

WEDNESDAY, May 5, 2021 -- Among children and adolescents, short- and long-term exposure to some ambient air pollutants may increase blood pressure, according to a systematic...

ACP Offers Guidance on Antibiotic Duration for Common Infections

WEDNESDAY, April 21, 2021 -- In a Best Practice Advice document issued by the American College of Physicians and published online April 6 in the Annals of Internal Medicine...

More News Resources

Subscribe to our Newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.